Drug intelligence / Profile preview

CBF-520

Development stage: Unknown
Lead developer: Caliway Biopharmaceuticals
Modality: Small Molecules
Administration: Subcutaneous

Overview

CBF-520 is a first-in-class investigational small molecule drug developed by Caliway Biopharmaceuticals for the reduction of subcutaneous fat. Administered via local injection, the drug is designed to selectively trigger apoptosis (programmed cell death) in adipocytes at the injection site. This mechanism allows for the effective reduction of localized fat deposits without causing tissue necrosis, inflammation, or significant systemic side effects. CBF-520 is being explored for both aesthetic fat reduction and therapeutic applications in conditions involving abnormal fat accumulation.

Beyond the preview

Go deeper on CBF-520.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBF-520.

Explore the full profile